Short answer: double-blind testing means that both participants and the researchers directly assessing them do not know who is receiving the treatment, placebo, or comparison condition. It is important because expectations can change behaviour, reporting, care, and interpretation.
Double-blind designs are especially common in clinical trials, but the principle applies more widely. If people know they are receiving a treatment, they may report improvement because they expect it. If researchers know who received the treatment, they may unconsciously interpret borderline cases more favourably.
What blinding protects against
Blinding protects against performance bias and assessment bias. Participants may behave differently if they know their group. Researchers may communicate enthusiasm without meaning to. Outcome assessors may rate symptoms or performance differently if they know what result they expect.
A placebo-controlled double-blind trial tries to make the groups feel as similar as possible except for the active ingredient or intervention being tested. This does not remove every source of error, but it makes the comparison much fairer.
When double-blinding is difficult
Not every study can be double-blind. Surgery, psychotherapy, classroom teaching, exercise programmes, and public policy interventions can be hard or impossible to conceal from participants or providers. In those cases, researchers may blind outcome assessors, use objective measures, standardise procedures, or rely on independent analysis.
Double-blind testing is important because human beings are not neutral measuring devices. Expectations matter. A good study design takes that seriously and tries to stop expectation from masquerading as evidence.